Adocia Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets
January 18 2021 - 12:00PM
Business Wire
Regulatory News:
Under the liquidity agreement entrusted by Adocia (Paris:ADOC)
to Kepler Capital Markets, the following resources were listed on
the liquidity account on December 31, 2020:
- 30,533 shares - € 104,644.60
- Number of executions on buy side on semester: 318 - Number of
executions on sell side on semester: 355 - Traded volume on buy
side on semester: 45,143 shares for € 353,656.52 - Traded volume on
sell side on semester: 47,151 shares for € 374,968.20
As a reminder:
• the following resources appeared on the last half year
statement on June 30, 2020 on the liquidity account:
- 32,541 shares - € 83,332.92
• the following resources appeared on the liquidity account when
the activity started:
- 15,026 shares - € 300,000.00
The liquidity agreement complies with AMF Decision n° 2018-01
dated 2nd July 2018, introducing liquidity agreements on equity
securities as permitted market practice
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring five clinical-stage products and three
products in preclinical-stage. The proprietary BioChaperone®
technological platform is designed to enhance the effectiveness
and/or safety of therapeutic proteins while making them easier for
patients to use. Adocia customizes BioChaperone to each protein for
a given application.
Adocia’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid-acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram. The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
Adocia preclinical pipeline includes three bi-hormonal products:
two combinations of rapid human insulin analogues and Pramlintide
(BioChaperone LisPram andBioChaperone AsPram) and a combination of
insulin glargine with Liraglutide (BioChaperone® GlaLira) for the
treatment of diabetes.
Adocia recently added a fourth program in preclinical with the
development of a hydrogel scaffold for cell therapy in the
treatment of type 1 diabetes. A first patent has been filed.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Reference Document filed with the
French Autorité des marchés financiers on April 22, 2020 (a copy of
which is available at www.adocia.com) and to the development of
economic conditions financial markets and the markets in which
Adocia operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Adocia or
not currently considered material by Adocia. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance, or achievements of Adocia to be materially
different from such forward-looking statements. This press release
and the information contained herein do not constitute an offer to
sell or the solicitation of an offer to buy Adocia shares in any
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210118005266/en/
Adocia Gérard Soula CEO contactinvestisseurs@adocia.com Ph: +33
4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund Gabriel
Managing Partner adocia@mc-services.eu Ph: +49 89 210 228 0
The Ruth Group Adocia Investor Relations USA James Salierno
Vice-President jsalierno@theruthgroup.com Ph.: +1 646 536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2023 to Apr 2024